Related Experiment Videos
Antibacterial activity of HRE 664, a new parenteral penem
1Department of Medical Microbiology and Immunology, Ruhr-University Bochum, Federal Republic of Germany.
Abstract:
The antibacterial activity of the new penem compound HRE 664 was evaluated in 451 clinical isolates, including ampicillin-resistant members of the family Enterobacteriaceae, Acinetobacter spp., Haemophilus influenzae, Staphylococcus aureus, and beta-hemolytic streptococci, and compared with those of piperacillin, ceftazidime, ceftriaxone, aztreonam, imipenem, and the penem compound Sch 34343. The new agent HRE 664 exhibited antibacterial activity comparable to that of the penem Sch 34343 and imipenem. The MICs of the new agent HRE 664 for 90% of the strains tested ranged from 1 to 4 micrograms/ml against Enterobacteriaceae and were 0.06 micrograms/ml for Staphylococcus aureus and 0.125 micrograms/ml for beta-hemolytic streptococci.
Insights
The novel penem compound HRE 664 demonstrates potent antibacterial activity against various clinical isolates, including resistant bacteria. Its efficacy is comparable to established antibiotics like imipenem.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing global health concern.
- Novel antibacterial agents are crucial for combating resistant bacterial infections.
- Penem compounds represent a class of beta-lactam antibiotics with broad-spectrum activity.
Purpose of the Study:
- To evaluate the antibacterial activity of the new penem compound HRE 664.
- To compare HRE 664's efficacy against clinical isolates with existing antibiotics.
- To determine the minimum inhibitory concentrations (MICs) of HRE 664.
Main Methods:
- Testing HRE 664 against 451 clinical bacterial isolates.
- Inclusion of resistant strains: Enterobacteriaceae, Acinetobacter spp., Haemophilus influenzae, Staphylococcus aureus, and beta-hemolytic streptococci.
- Comparative analysis with piperacillin, ceftazidime, ceftriaxone, aztreonam, imipenem, and Sch 34343.
Main Results:
- HRE 664 showed antibacterial activity comparable to Sch 34343 and imipenem.
- MICs for 90% of Enterobacteriaceae strains ranged from 1 to 4 µg/ml.
- MICs were 0.06 µg/ml for Staphylococcus aureus and 0.125 µg/ml for beta-hemolytic streptococci.
Conclusions:
- HRE 664 exhibits significant antibacterial potential against a range of clinical isolates.
- The compound demonstrates promising activity, particularly against Gram-positive bacteria.
- HRE 664 warrants further investigation as a potential therapeutic agent.